{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:34:19Z","timestamp":1793230459262,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","valueinhealthjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jval.2024.04.002","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T18:02:57Z","timestamp":1712944977000},"page":"1039-1045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Utilization, Expenditure, and Treatment Patterns Associated With Calcitonin Gene-Related Peptide Monoclonal Antibodies Reimbursed Subject to a Managed Access Protocol in Ireland"],"prefix":"10.1016","volume":"27","author":[{"given":"Amelia","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Finnigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Gorry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jval.2024.04.002_bib3","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","article-title":"Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"Stovner","year":"2018","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.jval.2024.04.002_bib4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10194-010-0217-0","article-title":"Prevalence of headache in Europe: a review for the Eurolight project","volume":"11","author":"Stovner","year":"2010","journal-title":"J\u00a0Headache Pain"},{"key":"10.1016\/j.jval.2024.04.002_bib5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41582-022-00763-1","article-title":"Global epidemiology of migraine and its implications for public health and health policy","volume":"19","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.jval.2024.04.002_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/164_2018_201","article-title":"Role of CGRP in migraine","volume":"255","author":"Edvinsson","year":"2019","journal-title":"Handb Exp Pharmacol"},{"issue":"5","key":"10.1016\/j.jval.2024.04.002_bib18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/14737167.2020.1822739","article-title":"Combining health technology assessment and health technology management to deliver cost-effective prescribing and cost containment\u2013the Irish experience","volume":"20","author":"Smith","year":"2020","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"10.1016\/j.jval.2024.04.002_bib20","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s10198-020-01181-0","article-title":"A\u00a0retrospective analysis of budget impact models submitted to the National Centre for Pharmacoeconomics in Ireland","volume":"21","author":"Lamrock","year":"2020","journal-title":"Eur J Health Econ"},{"issue":"4","key":"10.1016\/j.jval.2024.04.002_bib21","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/head.14068","article-title":"Erenumab patient characteristics, medication adherence, and treatment patterns in the United States","volume":"61","author":"Hines","year":"2021","journal-title":"Headache"},{"key":"10.1016\/j.jval.2024.04.002_bib22","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2147\/PPA.S346660","article-title":"Treatment Patterns for calcitonin gene-related peptide monoclonal antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: a retrospective US claims study","volume":"16","author":"Varnado","year":"2022","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.jval.2024.04.002_bib23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/head.14218","article-title":"Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: retrospective real-world study","volume":"62","author":"Gladstone","year":"2022","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.jval.2024.04.002_bib24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s10194-022-01536-3","article-title":"Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17-30 months","volume":"24","author":"Troy","year":"2023","journal-title":"J\u00a0Headache Pain"},{"key":"10.1016\/j.jval.2024.04.002_bib25","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1007\/s11845-023-03378-7","article-title":"Health technology management: the experience of a managed access approach to the reimbursement of dupilumab in Ireland","volume":"192","author":"Barrett","year":"2023","journal-title":"Ir J Med Sci"},{"issue":"2","key":"10.1016\/j.jval.2024.04.002_bib26","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/bcp.14393","article-title":"Sacubitril\/valsartan (Entresto) utilisation and prescribing patterns in the context of a reimbursement application system","volume":"87","author":"Kennedy","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.jval.2024.04.002_bib27","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s40273-016-0437-5","article-title":"The pharmacoeconomic evaluation process in Ireland","volume":"34","author":"McCullagh","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2024.04.002_bib28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40258-020-00586-5","article-title":"Effect of an online reimbursement application system on prescribing of lidocaine 5% medicated plaster in the Republic of Ireland","volume":"19","author":"Smith","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.jval.2024.04.002_bib29","author":"Ferrario"},{"issue":"9","key":"10.1016\/j.jval.2024.04.002_bib30","first-page":"632","article-title":"Private sector risk-sharing agreements in the United States: trends, barriers, and prospects","volume":"21","author":"Garrison","year":"2015","journal-title":"Am J Manag Care"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524023337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524023337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T14:23:12Z","timestamp":1722522192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301524023337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1098301524023337"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2024.04.002","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilization, Expenditure, and Treatment Patterns Associated With Calcitonin Gene-Related Peptide Monoclonal Antibodies Reimbursed Subject to a Managed Access Protocol in Ireland","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2024.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}